27173/2021/P-STORE

Corrigendum

AIIMS Rishikesh tender Enquiry No. T.No 24/RC/Pharmacy/Medicines/ 615/2021-RISH(Admn)
"Rate Contract document for procurement of Allergic disorder, ENT, Ophthalmic and Dermatology Medicines for Central Pharmacy AIIMS,Rishikesh"

S. No.	Original point	Revised (To be read as)
1.	**Instruction to Bidders; Point1. c.** No third-party manufacturers are allowed to quote for any drug.	Bidders with products manufactured on P2P basis from third party but having quality control of such products by in-house Quality Assurance Department are eligible to participate in tender.
2.	**Technical Evaluation Point b-o:** b. Bidder(s) must have a minimum of 03 (three) years of experience in supplying drugs & medical consumables (related to the items quoted in tender) to the Government / Corporate / PSU Hospitals c. in India. A t least 02 years, out of last 03 (three) years, experience must be with either of following: d. All India Institute of Medical Sciences (AIIMS), New Delhi e. Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh f. National Institute of Mental Health and Neuro-Sciences (NIMHANS), Bengaluru g. Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Pondicherry h. Sree Chitra Tirunal Institute for Medical Sciences and Technology, Kerala. i. Any Medical College/ hospital under Institute of National Importance. j. Ministry of Railways, Government of India. k. Central Government Health Scheme (CGHS), Ministry of Health & Family Welfare Government of India l. Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow. m. Vardhman Mahavir Medical College and Safdarjung Hospitals, New Delhi. n. Lady Harding Medical College & associated SSK & KSC Hospitals, New Delhi. o.	**Technical Evaluation Point b** b. Bidder(s) must have a minimum of 03 (three) years of experience in supplying drugs & medical consumables (related to the items quoted in tender) to the Government / Corporate / PSU Hospitals in India. A t least 02 years, out of last 03 (three) years, experience must be with either of following: 1. All India Institute of Medical Sciences (AIIMS), New Delhi 2. Postgraduate Institute of Medical Education and Research (PGIMER), Chandigarh 3. National Institute of Mental Health and Neuro-Sciences (NIMHANS), Bengaluru 4. Jawaharlal Institute of Postgraduate Medical Education & Research (JIPMER), Pondicherry 5. Sree Chitra Tirunal Institute for Medical Sciences and Technology, Kerala. 6. Any Medical College/ hospital under Institute of National Importance. 7. Ministry of Railways, Government of India. 8. Central Government Health Scheme (CGHS), Ministry of Health & Family Welfare Government of India 9. Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow. 10. Vardhman Mahavir Medical College and Safdarjung Hospitals, New Delhi. 11. Lady Harding Medical College & associated SSK & KSC Hospitals, New Delhi.
3.	**Technical Evaluation; Point p:** WHO–GMP Certificate: Valid WHO-GMP certificate and certificate issues/ attested by Centre/ state FDA of complete record of WHO-GMP certification from initiation till present including voids, if any.	**Technical Evaluation; Point c:** WHO–GMP Certificate: Valid WHO-GMP certificate and certificate issues/ attested by Centre/ state FDA of complete record of WHO-GMP certification from initiation till present including voids, if any.
4.	**Technical Evaluation; Point q-s:** q. WHO –CoPP (Certificate of Pharmaceutical Products): Valid CoPP, as per WHO norms, issued/ attested by Centre/ state FDA for each quoted product / item. r. Bidder must have recent experience, within last two years, for supplying salt, for which bid	**Technical Evaluation; Point d:** WHO –CoPP (Certificate of Pharmaceutical Products): Valid CoPP, as per WHO norms, issued/ attested by Centre/ state FDA for each quoted product/ item. OR Bidder must have recent experience, within last two years, for supplying salt, for which bid submitted, to developed country(ies).

	submitted, to developed countries.	For imported drug manufacturer must be Supplying/selling the product to/ in developed country(ies).
5.	**Technical evaluation; Point t.** Bidder(s) shall submit a Manufacturing & Market Standing Certificate / Experience Certificate issued by the Centre / State Drug Licensing Authority of the respective state that quoted product is manufactured and marketed by them since last 05 (Five) years.	**Technical evaluation; Point e.** Bidder(s) shall submit a Manufacturing & Market Standing Certificate / Experience Certificate issued by the Centre / State Drug Licensing Authority of the respective state that quoted product is manufactured andmarketed by them since last 03 (Three) years. Any firm who took over another manufacturer portfolio in past 3 years from date of publishing of this tender shall submit Manufacturing & Market Standing Certificate / Experience Certificate issued by the Centre / State Drug Licensing Authority stating time duration for which quoted product(s) was manufactured by either manufacturer totaling for 03 (Three) years. In such scenario, current manufacturer must fulfil other eligibility and technical criteria of tender document.
6.	**Technical evaluation; Point u & v:** u. In case of imported drugs, CoPP (Certificate of Pharmaceutical Products) / Import License and copy of the import registration of that particular molecule quoted in tender indicating list of products should be submitted as per WHO norms and '3-years' marketing experience certificate issued by Drug Controller. v. In case of newly introduced drugs/molecules, manufacturer can be eligible provided firm submits a certificate from DCGI, in this regard. In such cases, firm has to submit a Manufacturing & Marketing Certificate of molecule concerned from date of issue of Certificate by DCGI of newdrug to that firm. In such case Manufacturing & Marketing Certificate of 03 years is not cleared / completed, it will be relaxed accordingly.	**Technical evaluation; Point f & g:** f. In case of imported drugs, CoPP (Certificate of Pharmaceutical Products) / Import License and copy of the import registration of that particular molecule quoted in tender indicating list of products should be submitted as per WHO norms and '3-years' marketing experience certificate issued by Drug Controller. g. In case of newly introduced drugs/molecules, manufacturer can be eligible provided firm submits a certificate from DCGI, in this regard. In such cases, firm has to submit a Manufacturing & Marketing Certificate of molecule concerned from date of issue of Certificate by DCGI of newdrug to that firm. In such case Manufacturing & Marketing Certificate of 03 years is not cleared / completed, it will be relaxed accordingly.
7.	**Technical Evaluation; Point i:** **Quality Related Action taken by drug regulatory authority of India** Bidder has to provide certificate issued from regulatory authority, India that no warning has been issued or action has been taken in last 5years, in terms of quality of production and produced batches.	**Technical Evaluation; Point h: Quality Related Action taken by drugregulatory authority of India:** Bidder has to provide certificate issued from regulatory authority, India that no warning has been issued or actionhas been in last 5 years or from date of approval to market, whichever is latest, in terms of quality of production and produced batches.
8.	**Technical Evaluation; Point j:** Projection Capacity Assessment Certificate: Manufacturing firm must enclose certificate issued by Chartered Accountant/ concerned State Drug Controller indicating actual production detail of a particular molecule, batch-wise, for items quoted.	**Technical Evaluation; Point i:** Projection Capacity Assessment Certificate: Capacity Assessment Certificate: Manufacturing firm must enclose certificate as per **Annexure B (Attached below)** ******If any bidder already got prepared the format as per earlier clause with all required information for last three <u>financial years</u>* then it will also be accepted.
9.	**Technical Evaluation; Point k to point n**	**Technical Evaluation; Point j to point m**

27173/2021/P-STORE

10.	**Financial Evaluation; Point c:** Supplier has to submit a notarized affidavit on Indian Non Judicial Stamp Paper of Rs.10/- that bidder has not quoted price higher than previously supplied to any government Institute/ Organization/reputed Private Organization or DGS&D rate in recent past.	Supplier has to submit a notarized affidavit on Indian Non Judicial Stamp Paper of Rs.10/- that bidder has not quoted price higher than previously supplied to any government Institute/ Organization/ reputed Private Organization or DGS&D rate in *last three years or since the last change in M.R.P. whichever is latest*.

	Therefore, if at any stage it is found that supplier has quoted lower rates than those quoted in this tender; Institute (purchaser) would be given benefit of lower rates by Supplier and any excess payment if any, will become immediately payable to AIIMS, Rishikesh. If such affidavit is not submitted, tender will be summarily rejected. (Part of technical bid)	Therefore, if at any stage it is found that supplier has quoted lower rates than those quoted in this tender; Institute (purchaser) would be given benefit of lower rates by Supplier and any excess payment if any, will become immediately payable to AIIMS, Rishikesh. If such affidavit is not submitted, tender will be summarily rejected. (Part of technical bid)
7.	**(B) Special Conditions of Contract (SCC) / Contract terms; Point 3. Pharmacopoeia Specification; Point b):** It should be ensured that ISI Code No. is indicated on the packing and at the time of supplies has ISI Mark as well as Code No. as is the statutory requirement of the Bureau of Indian Standards.	**Point b). is omitted.** **Point c). to be read as b).**
8.	**Special Conditions of Contract (SCC) / Contract terms; Labelling; Point 5a.** Before making supply, approved rate contract holder should ensure that all primary packaging labels (i.e. Ampoules, vials, bottles, jars, tubes etc.) should be embossed, imprinted, stamped with letters, or requirements like “AIIMS-RISHIKESH SUPPLY NOT FOR SALE” stamp with permanent ink on each item/strip up to primary level.	Before making supply, approved rate contract holder should ensure that all primary, secondary and tertiary packaging labels (i.e. Ampoules, vials, bottles, jars, tubes etc.) should be embossed/ imprinted with barcode carrying information about batch number, date of manufacture, expiry date etc. Packing should have labels mentioning “AIIMS-RISHIKESH SUPPLY NOT FOR SALE” in permanent ink on each item/strip up to primary level.
9.	**Eligibility criteria cum Administrative cum Technical Evaluation Checklist (Annexure I):**	
	12. Please provide a notarized affidavit on Non Judicial stamp paper of Rs. 10/- in format given in Annexure-V that you have not quoted price higher than previously supplied to any government Institute/I/reputed Private I or DGS&D/GeM rate in last three years. If you don’t fulfil this criterion, your tender will be out rightly rejected.	12. Please provide a notarized affidavit on Non Judicial stamp paper of Rs. 10/- in format given in Annexure-V that you have not quoted price higher than previously supplied to any government Institute/reputed Private Institute or DGS&D/GeM rate in *last three years or since the last change in M.R.P. whichever is latest*. If you don’t fulfil this criterion, your tender will be out rightly rejected. * If the quoted product M.R.P. was changed within preceding three years of date of tender publish, then bidder has to submit documents as evidence of approval of such change from drug regulatory authority.
	21. Details of DD No of Tender fee: Date: Payable at:	21. Invoice against claim of supply/ sell of quoted molecules to developed country (ies)
	-	22. In-house quality assurance lab with accreditation certificate in name of bidder in reference to Instruction to Bidders; revised Point1. c.
	-	23. Details of DD No of Tender fee: Date: Payable at:
10.	**Annexure III:** I agree to maintain the following information in the Company’s record for a period of 8 years and shall make this available for verification to any statutory authorities	I agree to maintain the following information in the Company’s record for a period till 01 (one) year after all contractual obligations are over and shall make this available for verification to any statutory authorities

27173/2021/P-STORE

Corrigendum regarding Bill of Quantities (BOQ)/ Price schedule:

Column number 05 with heading “Units”:

In BOQ unit for quoting price against tablet or capsules is **to be read as one tab./cap.** instead of Stp. (strip)

27173/2021/P-STORE

Annexure B

CAPACITY ASSESSMENT CERTIFICATION

No.:

1. Name of the firm:
Address_____
Telephone_____
Email Id: _____

2. _____(Name of Manufacturer) is properly registered to supply pharmaceuticals or vaccines or medical devices in India, is in good legal and statutory standing with the responsible health authorities and is licensed as a primary manufacturer of the range of pharmaceuticals or vaccines or medical devices to be offered.

3.The production capacities for_____(name of Manufacturer) is as follows:

S.No. (As per tender document)	Medicine Name	Formulation	Strength	Production Capacity in Financial Year		
				2017-18	2018-19	2019-20

Certified by Charted Accountant
(Signature & Seal with date)

4. _____(Name of Manufacturer) retains full records of production batches and quality control test results, has demonstrated compliance with the M GMP quality standards during the past three years, and will exhibit these on request.

5. We hereby certify that the above information is true and accurate to the best of our knowledge.
Signature & Seal of the Authority of company _____
Date:
Full name (Printed) _____
Position _____